The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.

"The acceptance of Professor Freddie Hamdy’s GPS-ProMPT study in European Urology Oncology is an important milestone in our collaboration with the University of Oxford. These findings provide the scientific foundation for the ongoing GPS-ProtecT study, which has the potential to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence in localized prostate cancer," said Michael K. McGarrity, Chief Executive Officer of mdxhealth. "This publication supports our advancement of GPS with regard to guideline development, payer coverage, and physician adoption."

Lead author Dr Nikita Sushentsev, Cambridge University Hospitals NHS Foundation of Trust, commented, "The ProMPT findings demonstrate that patients with favorable GPS mdx scores achieved excellent long-term outcomes — including 92% freedom-from-failure at six years in active surveillance and up to 100% in surgery and radiotherapy cohorts — even among those with adverse clinical risk factors. This suggests GPS mdx can identify favorable tumor biology that traditional risk stratification alone would miss, with meaningful implications for how we counsel patients facing treatment decisions."